Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

Alvotech ALVO announced that it received a complete response letter (CRL) from the FDA for the biologics license application (BLA) for AVT02.  The biosimilar is being developed in collaboration with Teva Pharmaceutical TEVA.

Shares of ALVO and TEVA are trading down in pre-market hours.

The CRL from the FDA noted that certain deficiencies were found during a reinspection of Alvotech's Reykjavik facility. These deficiencies must be satisfactorily resolved before the application can be further approved.

AVT02 is a high-concentration biosimilar candidate forHumira (adalimumab), a drug used to treat autoimmune disorders such as rheumatoid arthritis and psoriasis. 

Alvotech provided the FDA with comprehensive responses to the inspection observations on Apr 3, 2023, and is awaiting communication from the agency assessing those responses.

The satisfactory outcome of the facility reinspection is key to the approval of the second BLA for AVT02.The second BLA contains data to support approval as a biosimilar and additional information bracing potential interchangeability designation. The Biosimilar User Fee Amendment goal date for the application review is June 28, 2023.

Teva Pharmaceutical is one of Alvotech's commercial partners.

TEVA’s shares have plunged 9.1% in the past year compared with the industry's 16% decline.

Zacks Investment Research
Image Source: Zacks Investment Research

Alvotech's shares have gained 38% in the past year against the industry's 12.6% decline.

Zacks Investment Research
Image Source: Zacks Investment Research

The company’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.

Alvotech Price and Consensus


Alvotech Price and Consensus

Alvotech price-consensus-chart | Alvotech Quote


Zacks Rank & Stocks to Consider

Currently, Alvotech has a Zacks Rank #3 (Hold).

Some better-ranked stocks for investors interested in the same sector are Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, both carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Loss per share estimates for Kala have narrowed from $18.34 to $16.54 for 2023 and from $14.41 to $13.12 for 2024 in the past 60 days. The company's shares have plunged 58.2% in the past year.

KALA's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.

Loss per share estimates for Allogene Therapeutics have narrowed from $2.83 to $2.44 for 2023 and from $2.69 to $2.46 for 2024 in the past 60 days.

ALLO's earnings beat estimates in each of the trailing four quarters, the average surprise being 8.33%. The company’s shares have plunged 38.8% in the past year.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report

Kala Pharmaceuticals, Inc. (KALA) : Free Stock Analysis Report

Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report

Alvotech (ALVO) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.